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Abstract
Background In this work, we aimed to identify molecular
epidermal growth factor receptor (EGFR) tissue biomarkers
in patients with ovarian cancer who were treated within the
phase III randomized European Organisation for Research and
Treatment of Cancer-Gynaecological Cancer Group (EORTC-
GCG) 55041 study comparing erlotinib with observation in
patients with no evidence of disease progression after first-line
platinum-based chemotherapy.
Methods Somatic mutations in KRAS, BRAF, NRAS,
PIK3CA, EGFR, and PTEN were determined in 318 (38 %)
and expression of EGFR, pAkt, pMAPK, E-cadherin and
Vimentin, and EGFR and HER2 gene copy numbers in 218
(26 %) of a total of 835 randomized patients. Biomarker data
were correlated with progression-free survival (PFS) and
overall survival (OS).
Results Only 28 mutations were observed among KRAS,
BRAF, NRAS, PIK3CA, EGFR, and PTEN (in 7.5 % of pa-
tients), of which the most frequent were in KRAS and
PIK3CA. EGFR mutations occurred in only three patients.
When all mutations were pooled, patients with at least one
mutation in KRAS, NRAS, BRAF, PIK3CA, or EGFR had
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longer PFS (33.1 versus 12.3 months; HR 0.57; 95 % CI 0.33
to 0.99; P=0.042) compared to those with wild-type tumors.
EGFR overexpression was detected in 93 of 218 patients
(42.7 %), and 66 of 180 patients (36.7 %) had EGFR gene
amplification or high levels of copy number gain. Fifty-eight
of 128 patients had positive pMAPK expression (45.3 %),
which was associated with inferior OS (38.9 versus
67.0 months; HR 1.81; 95 % CI 1.11 to 2.97; P=0.016).
Patients with positiveEGFR fluorescence in situ hybridization
(FISH) status had worse OS (46.1 months) than those with
negative status (67.0 months; HR 1.56; 95 % CI 1.01 to 2.40;
P=0.044) and shorter PFS (9.6 versus 16.1 months; HR 1.57;
95 % CI 1.11 to 2.22; P=0.010). None of the investigated
biomarkers correlated with responsiveness to erlotinib.
Conclusions In this phase III study, increased EGFR gene
copy number was associated with worse OS and PFS in pa-
tients with ovarian cancer. It remains to be determined wheth-
er this association is purely prognostic or is also predictive.
1 Introduction
Amajor focus of cancer therapy research over the past decade
has been in the targeting of cellular processes affecting cell
proliferation, differentiation, growth, and survival. One of the
best studied among these is the epidermal growth factor re-
ceptor (EGFR), given its dysregulation in the vast majority of
human tumors of epithelial origin [1]. EGFR is a member of
the ErbB family consisting of four tyrosine kinase (TK) recep-
tors: EGFR/ErbB-1, HER-2/neu (ErbB-2), HER-3 (ErbB-3),
and HER-4 (ErbB-4) [2]. Binding of specific ligands such as
epidermal growth factor (EGF) and transforming growth fac-
tor α (TGF-α) to the EGFR results in the dimerisation of the
receptor, tyrosine auto-phosphorylation, with subsequent ini-
tiation of the intracellular signaling pathways cascade.
Downstream signaling pathways include the ras-raf-mitogen-
activated protein kinase (Ras/Raf/MAPK) and the phos-
phatidylinositol 3-kinase (PI3K/AKT) pathways, which are
all involved in cell proliferation and survival [2].
EGFR overexpression is observed in up to 98 % of ad-
vanced epithelial ovarian cancers (EOCs) [3, 4] and has been
associated with a worse prognosis [3, 5], although data are
conflicting [6, 7]. The targeting of EGFR or its downstream
pathways, therefore, appears to be a promising strategy in
EOC. Monoclonal antibodies (mAbs), such as cetuximab
and panitumumab, bind competitively to the extracellular do-
main of EGFR, leading to internalization and degradation of
the receptor, while tyrosine kinase inhibitors (TKIs) like erlo-
tinib and gefitinib compete with ATP for binding to the recep-
tor’s intracellular TK domain, thereby inhibiting TK activity.
Both molecular strategies have been investigated in EOC
(Table 1).
Although several clinical prognostic factors have been
identified in EOC (e.g., age at diagnosis, extent of disease,
amount of residual disease after initial surgery, tumor grade,
and tumor histological subtype) [17, 18], molecular prognos-
tic markers, or even predictive biomarkers for targeted agents,
are still lacking. In other disease entities such as non-small cell
lung cancer (NSCLC) and metastatic colorectal cancer
(mCRC)—where anti-EGFR therapies have beenwidely stud-
ied—several predictive biomarkers for anti-EGFR agents
have been identified. EGFR protein expression as determined
by immunohistochemistry (IHC) was the first biomarker
claimed to predict a response in NSCLC. However, data have
been conflicting, and its association with sensitivity to anti-
EGFR therapies remains unclear [19–21]. Activating muta-
tions in EGFR exons 18 to 21 [22–24] and an increased
EGFR gene copy number may increase sensitivity to anti-
EGFR agents [19, 20, 25–28], whereas deregulation of down-
stream targets of the EGFR pathway (i.e., mutations in the
KRAS, NRAS, BRAF, or PIK3CA genes or loss of PTEN pro-
tein expression) have emerged as an important negative pre-
dictive factor for the efficacy of anti-EGFR mAbs [29–34].
However, following the initial response, NSCLC patients har-
boring activating EGFR mutations may become resistant to
TKIs due to an acquired secondary EGFR kinase domain mu-
tation, T790M [35]. While an increased HER2 gene copy
number in NSCLC may affect sensitivity to EGFR TKIs
[36–39], preclinical and clinical studies in mCRC have shown
cetuximab resistance in cases with HER2 gene amplification
[40, 41]. Additionally, in NSCLC, TKI responsivenessmay be
predicted by EGFR downstream proteins such as activated
(phosphorylated) AKT [19]. Furthermore, epithelial-
mesenchymal transition (EMT), a key player in cancer pro-
gression and metastasis, which is characterized by a loss in
expression of E-cadherin and a gain in vimentin expression, is
associated with resistance to gefitinib and erlotinib in NSCLC
[42, 43]. Thus far, the extensive data investigating responsive-
ness to anti-EGFR agents have focused mainly on NSCLC
and mCRC; data for ovarian cancer, on the other hand, are
scarce.
Studies with EGFR-targeted agents in EOC suggest that
only a subgroup of ovarian cancer patients might benefit from
these therapies (Table 1). However, Gordon et al. reported
44 % stable disease in a phase II study in patients with refrac-
tory recurrent EGFR-positive epithelial ovarian cancer treated
with erlotinib [8]. This finding led to the European
Organisation for Research and Treatment of Cancer-
Gynaecological Cancer Group (EORTC-GCG) 55041 trial,
in which ovarian cancer patients with no evidence of disease
progression following first-line platinum-based chemotherapy
were treated with erlotinib as maintenance therapy.
Unfortunately, in this unselected patient population, erlotinib
did not improve progression-free or overall survival. The aim
of the present explorative translational biomarker study based
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on the prospective EORTC-GCG 55041 trial [44] was to de-
termine the frequency of alterations of components of the
EGFR pathways and to correlate biomarker data with the ef-
ficacy of erlotinib.
2 Materials and Methods
2.1 Patient Population
In the EORTC-GCG 55041 phase III trial, eligible pa-
tients were those with histologically confirmed high-
risk FIGO stage I (grade 3, or aneuploid grade 1 or
2, or clear cell) or stages II–IV epithelial ovarian, pri-
mary peritoneal, or fallopian tube cancer [44]. All pa-
tients underwent first-line platinum-based chemotherapy
and showed no signs of progression at the end of che-
motherapy according to the Response Evaluation
Criteria In Solid Tumors (RECIST) criteria [45] and/
or the Gynecological Cancer Intergroup (GCIG) criteria
in the case of CA125-based evaluation at the end of
first-line treatment [46]. Overall, 835 patients were ran-
domized 1:1 to maintenance erlotinib 150 mg orally
daily for 2 years or observation. From the 835 patients
registered in the trial, 527 patients(63 %) consented to
optional translational research. Prospective bio-banking
was performed, and formalin-fixed paraffin-embedded
(FFPE) tissue sampled before and/or during first-line
chemotherapy was requested from the participating cen-
ters for this translational study. The FFPE histological
tissue was accepted independent of the site of biopsy—
for example, surgical specimens from primary ovarian
tumors, lymph nodes, or distant metastases. Patients
gave written informed consent by signing the separate
translational research informed consent form before any
study-specific procedure. The translational research
study and the informed consent forms were approved
by the ethics committees of the institutions involved.
The study was conducted in accordance with IHC good
clinical practice guidelines and the Declaration of
Helsinki, and was registered at ClinicalTrials.gov, num-
ber NCT00263822.
Table 1 Clinical trials reporting administration of anti-EGFR agents to patients with epithelial ovarian cancer
Study Treatment regimen Phase Patient population No. of pts Response
Erlotinib
Gordon et al. [8] 150 mg/d II Recurrent EGFR-positive 34 PR: 2 (6 %)
SD: 15 (44 %)
PD: 17 (50 %)
Blank et al. [9] Paclitaxel (175 mg/m2) and carboplatin
(AUC6) every 3 weeks and erlotinib
150 mg/d
II Primary
a: after optimal CRS, b:
after suboptimal
CRS, c: before CRS
56
a: 28, b: 23,
c: 5
CR (a): 8 (29 %)
CR (b): 3 (13 %)
Hirte et al. [10] Carboplatin (AUC5) every 3 weeks
and erlotinib 150 mg/d
II Recurrent
a: platinum-sensitive
b: platinum-resistant
50
a: 33
b: 17
CR (a): 3 (9 %)
PR (a): 14 (42 %)
PR (b): 1 (6 %)
Gefitinib
Schilder et al. [11] 500 mg/d II Recurrent 27 PR: 1 (3.7 %)
PFS>6 m: 14.8 %
Posadas et al. [12] 500 mg/d II Recurrent 24 CR: 0
PR: 0
SD: 9 (38 %)
Wagner et al. [13] Tamoxifen 40 mg/d and gefitinib
500 mg/d
II Recurrent 56 SD: 16 (28.6 %)
Pautier et al. [14] Paclitaxel (175 mg/m2) and carboplatin
(AUC5) every 3 weeks and gefitinib
500 mg/d
II Recurrent
a: platinum-resistant
b: platinum-sensitive
68
a: 26
b: 42
CR (a): 1 (3.8 %)
CR (b): 10 (23.8 %)
PR(a): 4 (15.4 %)
PR (b): 16 (38.1 %)
Cetuximab
Schilder et al. [15] Initial dose 400 mg/m2 and 250 mg/m2
weekly for two 3-week cycles
II Recurrent 25 PR: 1 (4 %)
SD: 9 (36 %)
Secord et al. [16] Initial dose 400 mg/m2, followed by weekly
infusion of 250 mg/m2 and carboplatin
(AUC6) every 3 weeks
II Recurrent platinum-sensitive
EGFR positive
26 CR: 3 (11.5 %)
PR: 6 (23 %)
SD: 8 (30.8 %)
AUC area under the curve, CR complete response, CRS cytoreductive surgery, No. of pts number of evaluable patients, PR partial response, SD stable
disease
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2.2 Molecular Tissue Biomarker Analyses
The translational analyses were performed at the Department
of Oncology, Division of Gynecological Oncology, at the
Catholic University Leuven (Leuven, Belgium), the Vesalius
Research Center at the Flanders Institute for Biotechnology
(VRC/VIB3) (Leuven, Belgium), and the University of
Colorado Comprehensive Cancer Center (Aurora, CO,
USA). Tumor tissues were sent as FFPE blocks, eppendorf
tubes or glass slides. All tumor tissue samples were checked
for quality, tissue integrity, and tumor content on a 5-μm he-
matoxylin and eosin (H&E) stained section. Tissue microar-
rays (TMAs) for the IHC analyses were constructed using a
manual tissue puncher/arrayer (Beecher Instruments, Silver
Spring, MD, USA). Tumor DNA was extracted using a
phenol-chloroform method after macrodissection of the
marked tumor region on the H&E slide. Biopsies with a low
estimated tumor percentage on H&E and those failing to yield
sufficient DNA after extraction were excluded (n=27).
2.2.1 Immunohistochemistry
Immunohistochemical analyses were performed on the con-
structed TMAs or individual slides using methods and assess-
ment criteria described elsewhere [25]. The following primary
antibodies were used for IHC: EGFR (Cell Signaling
Technology, Inc., Beverly, MA, USA) diluted at 1:50, phosphor-
ylated Akt (Ser473) at 1:50, phosphorylated p44/42 MAPK
(Thr202/Tyr204; E10) monoclonal antibody (Cell Signaling
Technology, Inc.) at 1:50, vimentin antibody V9 (Dako/Agilent
Technologies, Carpinteria, CA, USA), and E-cadherin antibody
H-108 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA).
The percentage of total tumor cells within each staining intensity
category [0 (no staining), 1+ (weak), 2+ (moderate), 3+ (strong)]
was reported. A hybrid (H)-score was then generated based on
the fraction of staining cells in each intensity category. The H-
score was calculated by completing the formula (% cells of 0
intensity x 0)+(% of 1+ intensity x 1)+(% of 2+ intensity x 2)+
(% of 3+ intensity x 3), producing a final H-score with a range of
0–300 [25]. For statistical analyses, the immunohistochemical
results of EGFR, E-cadherin, pMAPK, and pAkt were analyzed
in a binary fashion due to the skewed distribution of the results.
2.2.2 Fluorescence In Situ Hybridization (FISH) Analyses
We analyzed the EGFR gene copy number per cell using the LSI
EGFR SpectrumOrange/CEP 7 SpectrumGreen Probe (Abbott
Molecular, Des Plaines, IL, USA), as previously described [19,
25]. Tumor specimens were classified into six FISH strata ac-
cording to the frequency of cells with each EGFR gene copy
number and referred to the chromosome 7 centromere, as fol-
lows: (1) disomy (three or four copies in <10% of cells), (2) low
trisomy (three copies in 10% to <40%of cells and four copies in
<10 % of cells), (3) high trisomy (three copies in ≥40 % of cells
and four copies in <10%of cells), (4) low polysomy (four copies
in 10 % to <40 % of cells), (5) high polysomy (four or more
copies in ≥40% of cells), and (6) gene amplification (presence of
loose or tight EGFR gene clusters with ≥4 copies, EGFR gene-
to-CEP 7 ratio≥2, or 15 copies of EGFR per cell in ≥10 % of
cells). The high polysomy and gene amplification categories
were considered to indicate a high EGFR copy number
(EGFR-FISH positive), and the other categories were considered
to indicate no significant increase in the EGFR copy number
(EGFR-FISH negative), as previously described [34, 47].
Dual-target, dual-color HER2 FISH assays were performed
using the PathVysion HER-2 DNA probe kit (Abbott
Molecular), which includes the LSI HER-2 SpectrumOrange
and the CEP 17 SpectrumGreen probes. The reference slide
(stained with H&E) was the adjacent section on which the dom-
inant tumor foci were identified, and copy numbers of the HER2
gene and chromosome 17 centromere probes were assessed and
recorded independently in at least 50 non-overlapping nuclei with
intact morphology. Analysis was performed blinded to the pa-
tients’ clinical characteristics. Based on the mean number of cop-
ies of the HER2 gene and chromosome 17 centromere per cell,
patients were classified into three strata: negative for HER2 am-
plification when the mean HER2/mean CEP17 ratio was <1.8,
positive for HER2 amplification when then mean HER2/mean
CEP17 ratiowas >2.2, and equivocalwhen themeanHER2/mean
CEP17 ratio was between 1.8 and 2.2, in which case a second
observer independently scored 50 tumor cells, and the final clas-
sification was assessed based on the results in all 100 cells.
2.2.3 Somatic Mutation Profiling
The COSMIC (Catalogue Of Somatic Mutations In Cancer)
database [48] was queried for the most frequent mutations oc-
curring in commonly mutated oncogenes related to the EGFR
pathway, which resulted in coverage of >97 %, >94 %, >97 %,
>79 %, >65 %, and >7 % for KRAS, BRAF, NRAS, PIK3CA,
EGFR, and PTEN, respectively. DNAwas aliquoted into 384-
well plates and genotyped centrally at the Vesalius Research
Center (Leuven, Belgium). iPLEX technology was used on a
MassARRAY Compact Analyser (Sequenom Inc., San Diego,
CA, USA), as described by De Roock et al. [31]. DNA of a
sample was considered of sufficient quality when more than
75 % of mutations were reliably genotyped. A sample was
considered wild-type for a given gene when themost frequently
mutated sites in this gene did not show a mutation.
2.2.4 EGFR Sequencing
Targeted re-sequencing of EGFR was performed to identify
potential somatic mutations that were not assessed in the
Sequenom hotspot mutation panel. In particular, EGFR was
sequenced using the TruSeq Custom Amplicon Kit on an
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Illumina MiSeq sequencer (Illumina, Inc., San Diego, CA,
USA). Custom oligo probes targeting EGFR exons were
designed using DesignStudio (Illumina, Inc.). Amplicons were
generated in an extension-ligation reaction across the region of
Table 2 Baseline patient characteristics: overall study population (n=835) and translational study population (mutation analysis n=318, FISH and
immunohistochemical analysis n=218)
Parameter Translational Overall P value
Mutation group (n=318) FISH/IHC group (n=218) (n=835) Mutation vs overall FISH/IHC vs overall
No. % No. % No. %
Age (years) 0.300 0.532
Median 59.5 59.0 59.0
Range 31–85 31–85 19–85
WHO performance status 0.987 0.134
0 213 67 137 62.8 559 66.9
1 105 33 81 37.2 276 33.1
FIGO stage 0.561 0.128
I 25 7.9 21 9.6 57 6.8
II 27 8.5 19 8.7 62 7.4
III 212 66.7 144 66.1 563 67.4
IV 54 17 33 15.1 152 18.2
Unknown 0 0 1 0.5 1 0.1
Histological grade 0.001 0.002
Grade 1 12 3.8 9 4.1 58 6.9
Grade 2 58 18.2 38 17.4 152 18.2
Grade 3 172 54.1 127 58.3 388 46.5
Unknown 76 23.9 44 20.2 237 28.4
Histological type 0.055 0.285
Serous 205 64.5 134 61.5 521 62.4
Mucinous 7 2.2 6 2.8 14 1.7
Clear cell 23 7.2 18 8.3 51 6.1
Endometrioid 28 8.8 16 7.3 61 7.3
Undifferentiated 8 2.5 7 3.2 21 2.5
Other/Unknown 47 14.8 37 17 167 20
Treatment arm 0.995 0.795
Erlotinib 160 50.3 108 49.5 420 50.3
Observation 158 49.7 110 50.5 415 49.7
First-line chemotherapy 0.612 0.693
Platinum alone 12 3.8 11 5 36 4.3
Platinum doublet or triplet 306 96.2 207 95 799 95.7
Response at end of first-line chemotherapy* 0.221 0.550
Complete remission 246 77.4 163 74.8 602 72.1
Partial remission 65 20.4 49 22.5 204 24.4
Stable disease 7 2.2 6 2.8 29 3.5
Overall Survival (months) 0.272 0.588
Median 66.99 50.99 51a–59b
Progression-free survival (months) 0.923 0.776
Median 12.8 13.04 12.4b-12.7a
* according to the RECIST criteria and/or the GCIG criteria in the case of CA125-based evaluation at the end of first-line treatment [45, 46] a erlotinib
armb observation arm
FIGO Fédération Internationale de Gynécologie et d’Obstétrique, WHO World Health Organization
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interest and amplified in a subsequent PCR, which also incor-
porates two unique sample-specific indexes, following theman-
ufacturer’s instructions. After pooling, the samples were se-
quenced on an Illumina MiSeq in a 2x150-bp paired-end se-
quencing run using a v2 flow cell. Data were mapped with the
Burrows-Wheeler Aligner (bwa-0.5) [49] to the human refer-
ence genome hg19. The Genome Analysis Toolkit (GATK ver-
sion 1.6; Broad Institute) was further used to process the data,
and variants and indels were called by the Unified Genotyper
and Dindel, respectively [50, 51]. The mutations were further
filtered [52] andmanually curated in IGV. EGFR re-sequencing
was successful if the average coverage per sample was >100x.
2.3 Statistical Analyses
All statistical analyses for the translational study of the
EORTC-GCG 55041 trial were performed centrally at the
headquarters of the EORTC in Brussels (Belgium). The
Table 3 Correlation of
biomarker results with overall
survival (OS) and progression-
free survival (PFS)
Biomarker n OS PFS
Mos. HR (95 % CI) P Mos. HR (95 % CI) P
KRAS
Wild-type 309 NR 12.5
Mutation 9 67.0 1.08 (0.43–2.69) 0.876 14.1 0.90 (0.42–1.91) 0.784
PIK3CA
Wild-type 306 67.0 12.4
Mutation 12 NR 0.53 (0.17–1.65) 0.262 NR 0.36 (0.15–0.86) 0.017
EGFR
Wild-type 315 NR 12.9
Mutation 3 37.9 1.80 (0.53–6.15) 0.345 4.01 2.09 (0.67–6.54) 0.195
KRAS, NRAS, BRAF, PIK3CA or EGFR
Wild-type 294 NR 12.3
Mutation 24 67.0 0.75 (0.38–1.49) 0.413 33.1 0.57 (0.33–0.99) 0.042
EGFR IHC
Negative 125 51.0 11.7
Positive 93 46.1 1.23 (0.85–1.78) 0.273 13.0 1.03 (0.76–1.39) 0.835
EGFR FISH
Negative 114 67.0 16.1
Positive 66 46.1 1.56 (1.01–2.40) 0.044 9.6 1.57 (1.11–2.22) 0.010
pAkt-IHC
Negative 108 49.1 11.6
Positive 27 53.7 0.89 (0.48–1.63) 0.696 13.8 0.65 (0.39–1.09) 0.100
pMAPK-IHC
Negative 70 67.0 15.7
Positive 58 38.9 1.81 (1.11–2.97) 0.016 8.1 1.42 (0.96–2.10) 0.077
E-cadherin-IHC
Negative 64 67.0 10.5
Positive 71 51.0 0.99 (0.61–1.62) 0.970 13.1 0.87 (0.59–1.28) 0.491
Vimentin-IHC
Negative 30 NR 13.8
Intermediate 58 49.0 1.61 (0.78–3.30) 13.1 0.88 (0.53–1.45)
Positive 40 39.6 2.07 (0.99–4.34) 0.139 9.1 1.18 (0.70–1.98) 0.430
HER2-FISH
Negative 30 49.1 22.1
Equivocal 23 51.0 1.07 (0.48–2.35) 8.8 2.13 (1.13–4.01)
Positive 53 67.0 0.97 (0.49–1.89) 0.965 13.7 1.51 (0.87–2.63) 0.061
CI confidence interval, FISH fluorescence in situ hybridization, HR hazard ratio, IHC immunohistochemistry,
Mos. months, NR not reached, OS overall survival, PFS progression-free survival. Bold entries indicate statisti-
cally significant p values (P <0.05)
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sample size of the trial (n=835) was based on the primary
endpoint, progression-free survival (PFS), to detect an in-
crease of 25 % in the median PFS from 15 to 18.75 months
[44]. Secondary endpoints were overall survival (OS), toxici-
ty, occurrence of rash, and quality of life. OS and PFS were
defined as the time from randomization to the date of the event
(death and death or progression, respectively). Time-to-event
analyses were investigated via the Kaplan-Meier method with
hazard ratios (HR) obtained through Cox regression and com-
pared via a nonparametric log-rank test stratified for treatment
(where possible). Predictiveness for treatment effect was
assessed via Cox regression using an interaction test with the
allocated protocol treatment (erlotinib versus observation). All
tests were nonparametric two-sided tests, evaluated at the 5 %
significance level. No correction for multiplicity was made,
and the 5 % level was used as a screening measure rather than
a formal hypothesis test.
3 Results
3.1 Patient Characteristics
Tumor tissues were available for 358 of the 527 patients
(68 %) who consented to optional translational research.
Mutation data were available for 318 patients and FISH and
IHC data for 218 patients. The main reason for the different
numbers was due to the fact that DNA extraction was possible
in most samples, where IHC or FISH analysis was not achiev-
able due to technical reasons. Detailed patient characteristics
are summarized in Table 2. With regard to important baseline
parameters (e.g., age, stage, histological type and grade) no
significant imbalances between the overall study population
and the translational study population were apparent, except
for histological grade (with more high-grade tumors and fewer
patients with unknown histological grade in the translational
study population).
3.2 Frequency of Alterations inMolecular EGFRPathway
Biomarkers and Clinical Outcome
Table 3 summarizes the correlation between biomarker results
and both PFS and OS. The distribution of selected baseline
patient characteristics between the molecular marker results
are summarized in Online Resource 1.
3.2.1 EGFR Protein Expression
EGFR protein expression was evaluated by immunohisto-
chemistry in 218 patients. Of these, 42.7 % had EGFR mem-
branous staining (EGFR IHC-positive) (Fig. 1). EGFR protein
expression had no impact on OS (HR: 1.23, P=0.273) or PFS
(HR: 1.03, P=0.835).
3.2.2 EGFR Gene Copy Number
We assessed EGFR gene copy number by FISH in 180
patients. Patients with high polysomy and gene amplification
categories were combined and designated EGFR FISH-posi-
tive, and all other categories were categorized as EGFR
FISH-negative, as previously described [19]. Representative
images of these two classes are shown in Fig. 2. FISH-
positive patients represented 36.7 % of the total group, with
63.3 % FISH-negative. Next, we correlated EGFR FISH cate-
gories with clinical outcome (Fig. 3). Compared to FISH-
negative patients, EGFR FISH-positive patients had
Fig. 1 EGFR
immunohistochemical staining.
A hybrid (H)-score was generated
based on the fraction of staining
cells in each intensity category
[0 (no staining), 1+ (weak), 2+
(moderate), 3+ (strong)]. The
H-score was calculated by
completing the formula (%
cells of 0 intensity x 0)+(% of
1+ intensity x 1)+(% of 2+
intensity x 2)+(% of 3+
intensity x 3), with the overall
score ranging from 0 to 300.
Panels illustrate specimens
graded with score 0 (a), score 80
(low expression, b), score 170
(moderate expression, c) and
score 280 (high expression, d)
(image magnification 40x)
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statistically significantly shorter OS (median 46.1 versus
67.0 months, HR=1.56 [95 % CI 1.01-2.40], P=0.044) and
shorter PFS (median 9.6 versus 16.1 months, HR=1.57
[95 % CI1.11–2.22], P=0.010). However, EGFR gene copy
number could not predict responsiveness to erlotinib (Fig. 4).
3.2.3 pAkt and pMAPK Expression by IHC
Immunohistochemical evaluation of pAkt and pMAPK was
successful in 135 and 128 patients, respectively, with 27 cases
(20 %) for pAkt and 58 cases (45.3 %) for pMAPK classified
as positive. Positive pMAPK expression was seen mainly in
serous tumors. While no effect of pAkt IHC positivity was
seen on OS (HR: 0.89, P=0.696) or PFS (HR: 0.65, P=
0.100), pMAPK IHC positivity was significantly associated
with worse OS (HR: 1.81, P=0.016) (Fig. 3). pMAPK did not
seem to have predictive value (Fig. 4).
3.2.4 Epithelial-Mesenchymal Transition (EMT) Status
by IHC
Changes in EMTstatus including the expression of E-cadherin
as epithelial marker and vimentin as mesenchymal marker
were successfully evaluated by IHC in 135 and 128 patients,
respectively. The protein expression of E-cadherin was con-
sidered high in 52.6 % of patients, while vimentin was cate-
gorized as low (≤30), intermediate (30–130), or high (>130).
High protein expression of vimentin was observed in 31.3 %.
Neither E-cadherin nor vimentin IHC correlated with outcome
or were predictive (Table 3).
3.2.5 HER2 Gene Copy Number Status by FISH
HER2 FISH was assessable in 106 patients with available
tumor tissue and classified as positive (>2.2) in 50 % of cases.
No significant correlation between HER2 copy number status
and outcome was observed (Table 3).
3.2.6 Mutation Analysis
Hotspot mutation profiling of 20, 2, 20, 33, 15, and 8
somatic mutations in KRAS, BRAF, NRAS, PIK3CA,
EGFR, and PTEN, respectively, using Sequenom
MassARRAY was technically successful for 318 cases
(Online Resource 2). Overall, only 28 mutations were ob-
served among 24 samples (7.5 %). Of the genes analyzed,
PIK3CA and KRAS were the most frequently mutated.
PIK3CA mutations were present in 3.8 % (12/318) of
the samples, most of which were located in exon 9
(4/12; 33 %) or exon 20 (4/12; 33 %). KRAS mutations
were detected in nine samples (2.8 %), nearly all within
codon 12 (8/9, 88.9 %). EGFR mutations occurred in only
three patients. EGFR re-sequencing was successful in 59
of 64 samples. The average coverage of EGFR exons for
these samples was 590x. No additional somatic mutations
were detected in any of the EGFR exons. Mutations in
PTEN were not detected. Mutations occurred less frequent-
ly in serous cancers (7/206 [3 %] in serous versus 17/112
[15 %] in non-serous cancers; see Online Resource 1).
The limited frequency of mutated samples in this analysis
prevents a meaningful evaluation of clinical outcomes in
relation to individual mutations. As such, patients with at
least one mutation in the EGFR signaling cascades were
pooled. Patients with at least one mutation in KRAS,
NRAS, BRAF, PIK3CA, or EGFR had longer PFS (33.1
versus 12.3 months, mean difference=20.8 months, P=
Fig. 2 EGFR determined by fluorescence in situ hybridization. FISH
was performed with the EGFR (red)/CEP7 (green) probe (Abbott Molec-
ular, Des Plaines, IL, USA). Panels illustrate specimens representing low
gain in gene copy number per cell (EGFR FISH-negative) (a), high (high
polysomy=b; gene amplification=c) gain in gene copy number per cell
(EGFR FISH-positive)
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0.042) compared to those with wild-type tumors (Fig. 3),
but among the former, there was no significant benefit of
erlotinib over observation (Fig. 4). No significant differ-
ence in OS was seen when all mutations were pooled.
4 Discussion
Most data that have added to our understanding of molecular
responsiveness to anti-EGFR agents have been derived from
Fig. 3 Kaplan-Meier curves for overall survival and progression-free survival. Data were analyzed according to presence of mutations (top), pMAPK
immunohistochemistry (middle), and EGFR gene copy number (bottom)
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Fig. 4 Kaplan-Meier curves for overall survival and progression-free survival according to treatment allocation. Data were analyzed according to
presence of mutations (top), pMAPK immunohistochemistry (middle), and EGFR gene copy number (bottom)
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well-conducted trials in mCRC and NSCLC. To date, only
limited data on EGFR pathway biomarkers are available for
epithelial ovarian cancer and, even more specifically, in pa-
tients being treated with anti-EGFR therapies. The EORTC-
GCG 55041 trial is the first randomized phase III trial investi-
gating the use of maintenance erlotinib in patients with ovari-
an, peritoneal or fallopian tube cancer. In this project, we in-
vestigated the status of EGFR and related pathways using im-
munohistochemistry, FISH, hotspot mutation analysis, and
DNA sequencing to determine the frequency of these alter-
ations in patients with ovarian cancer and to correlate these
biomarker data with outcome andwith the efficacy of erlotinib.
In this study, EGFR overexpression was found with IHC in
39.4% of patients, but we could not validate EGFR expression as
a poor prognostic marker. The prognostic role of EGFR expres-
sion in EOC remains controversial. While some studies associate
EGFR overexpression with poor clinical outcome [3, 5], others
have shown no effect [6, 7]. However, we found a statistically
significant correlation with PFS and OS for EGFR copy number
status. Patients who were EGFR FISH-positive had worse OS
(46.1 months) than those who were EGFR FISH-negative
(67.0 months) (HR: 1.56; 95 % CI 1.01–2.40; P=0.044). The
median PFS was 9.6 months he EGFR FISH-positive patients
and 16.1 months for EGFR FISH-negative patients (HR: 1.57;
95 % CI 1.11–2.22; P=0.010). However, EGFR amplification
was not predictive of erlotinib responsiveness, suggesting that
EGFR copy number status may be a prognostic rather than pre-
dictive factor for erlotinib. Results reported by Lassus et al. also
support the assumption that EGFR copy number serves as a
prognostic biomarker in EOC, showing that an increased EGFR
copy number was associated with shorter OS and PFS [53].
In contrast to mCRC and NSCLC, EGFR mutation did not
predict responsiveness to erlotinib treatment, nor did gain-of-
function mutations in the EGFR signaling cascades (KRAS,
BRAF, NRAS, and PIK3CA). The limited frequency of mutated
samples, however, prevents meaningful evaluation of clinical
outcomes in relation to these mutations. However, when
pooling all mutations together, patients with at least one muta-
tion in either KRAS, NRAS, BRAF, PIK3CA or EGFR had a
longer PFS (33.1 months) compared to those with wild-type
tumors (12.3months) (HR: 0.57; 95%CI 0.33-0.99;P=0.042).
With the exception of pMAPK expression, which was asso-
ciated with shorter overall survival, none of the investigated
biomarkers demonstrated prognostic significance or were pre-
dictive of erlotinib efficacy in our translational study popula-
tion. Some limitations to the study, however, must be taken into
consideration. Although there was a compelling body of basic
and preclinical evidence for launching this study, it failed to
show a benefit of erlotinib over standard management
(observation) [44], making it very difficult to evaluate predic-
tive biomarkers. In addition, 26 % of the patients stopped erlo-
tinib due to side effects.Moreover, obtaining a full analysis data
set with complete results for all tissue samples submitted to
molecular analysis remains a challenge. The different tech-
niques often require fresh tissue or a sufficient amount of ade-
quate tissue or tumor cells. Thus, tissue quality and technical
performance may also significantly affect biostatistical results.
Finally, EOC represents a genetically complex disease, render-
ing simple translation of the biomarker data difficult.
Although the EGFR pathway appears to play an important
role in ovarian cancer, particularly in tumor development, tumor
cell survival, and metastasis, it is not yet clear how this pathway
can be exploited to yield a therapeutic benefit. In the future, rather
than using an unselected patient population, it will be important
to select patients based only on molecular characteristics for ran-
domized studies investigating EGFR-targeted treatments. In the
event that findings are similar to those in breast cancer for
HER2 and trastuzumab or in NSCLC for EGFR and gefi-
tinib, where increased copy number is a poor prognostic
feature but a good predictor of response, EGFR copy num-
ber status may represent a criterion for selecting EOC pa-
tients for those clinical trials.
In conclusion, in this translational study on the EORTC-
GCG 55041 trial, the presence of EGFRmutations or gain-of-
function mutations in the EGFR signaling cascades (KRAS,
BRAF, NRAS, and PIK3CA), increased EGFR copy number,
and positive EGFR protein overexpressionwere not predictive
of erlotinib efficacy. However, increased EGFR copy number
seems to have a prognostic role. Therefore, EGFR FISH anal-
ysis may be interesting for further investigation as a criterion
for selecting patients for prospective studies on erlotinib or
other anti-EGFR therapies in EOC.
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